Skip to main content

Table 1 Patient characteristics and prior therapy

From: A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Characteristic N (%)
Median Age (range) 65 (57–72)
Gender
 Male 13 (93%)
 Female 1 (7%)
Histology
 Clear cell 13 (93%)
 Papillary 1 (7%)
ECOG
 0 9 (64%)
 1 5 (36%)
IMDC risk group
 Favorable 1 (7%)
 Intermediate 12 (86%)
 Poor 1 (7%)
Metastatic sites
 Lymph nodes 8 (57%)
 Bone 8 (57%)
 Lung 7 (50%)
 Liver 3 (21%)
Number or prior therapies
 1 12 (86%)
 2 1 (7%)
 3 1 (7%)
Most recent therapy
 Sunitinib 8 (57%)
 Axitinib 3 (21%)
 Pazopanib 2 (14%)
 HIF-2a inhibitor 1 (7%)
Best response to most recent therapya
 PR 3 (21%)
 SD 9 (64%)
 PD 1 (7%)
 Median duration on most recent therapy (months)a 18 (3–100)
  1. aMissing for one patient